Authors


P. Connor Johnson, MD

Latest:

Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas

P. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma.


W. Iris Zhi, MD, PhD

Latest:

Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations

This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.


Robert H. Vonderheide, MD, DPhil

Latest:

Robert H. Vonderheide, MD, DPhil, Discusses Genomic Correlates of Response to Chemoimmunotherapy in PDAC

Biosignatures data from the PRINCE trial show sophisticated precision approaches may be necessary to optimize chemoimmunotherapy use in pancreatic ductal adenocarcinoma.


Gregory Riely, MD, PhD

Latest:

Improving Outcomes in Non-Small Cell Lung Cancer: Future Directions in Care

Best treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.



Jennifer A. Vencill, PhD, LP

Latest:

Psychosocial Approach to Sexual Dysfunction During and After Cancer Treatment

Jenifer A. Vencill, PhD, LP, highlighted that sexual dysfunction can negatively impact patients' quality of life, and how she aims to bring more awareness to this issue.



Domenica Lorusso, MD, PhD

Latest:

Phase 3 KEYNOTE-A18 Trial Data Are ‘Practice Changing’ for Cervical Cancer

Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.


Justin Gainor, MD

Latest:

Face-Off: Award Presentations and Event Conclusion

Judy concludes the event and presents the awards.





Terence T. Sio, MD, MS

Latest:

Face-Off: Award Ceremony

Following a comprehensive debate on the treatment of patients with non–small cell lung cancer, Edward Kim, MD, presents the winning team with the title of victors of this CancerNetwork® Face-Off event.


Jeffrey Triska, MD

Latest:

Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head Mass

Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.



Gabriel Solorzano, MD

Latest:

Predictors of Poor Adherence to Follow-up Care in Survivors of Childhood Cancer

Rahiya Rehman, MD, and co-investigators, research the importance of poor follow-up and care for survivors of childhood cancer.



Zofia Piotrowska, MD

Latest:

OncView™ Podcast: EGFR Exon 20 Insertion as a Therapeutic Target in NSCLC

In an OncView™ program, Zofia Piotrowska, MD, touched on testing, treatment approaches, and therapeutic options for EGFR exon 20 insertion mutations in non–small cell lung cancer.



Juan Pablo Alderuccio, MD

Latest:

Oncology Peer Review On-The-Go: Current Treatments in Marginal Zone Lymphoma

Juan Pablo Alderuccio, MD, spoke with CancerNetwork® about a review article on the treatment of marginal zone lymphoma published in the journal ONCOLOGY®.



Farwa Zehra, MBBS

Latest:

Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia

Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.





Ramez Eskander, MD

Latest:

Data May Support Pembrolizumab/Chemo as New SOC in Endometrial Cancer

Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.



Steven Vogl, MD

Latest:

HER2+ Advanced Breast Cancer: Selecting Third-Line Therapy

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss clinical implications of a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.


Andrés Gómez De León, MD

Latest:

Tandem 2022 Presentation: Haploidentical versus Matched Unrelated Donor Transplants for Lymphomas Using Post-transplant Cyclophosphamide

This article was written for and by CancerNetwork partner, the American Society for Transplantation and Cellular Therapy.